Dow Plunges Over 800 Points as Investors Flee Tech
*By Kavitha Shastry*
U.S. stocks accelerated their losses Wednesday, with the Dow tumbling more than 800 points for its biggest point drop since February.
Shares of Amazon ($AMZN) and Microsoft ($MSFT) were down more than 4 percent late in the trading day, while Jack Dorsey's Twitter ($TWTR) and Square ($SQ) were both down more than 7 percent.
"Valuation is just coming to a bit more realistic levels in the tech sector," said John Petrides, Managing Director at Point View Wealth Management. "How many times have we spoken about tech being the driving sector for the market returns.
"Twenty-six percent of the S&P 500, the FAANG stocks equalling 45 percent of the Nasdaq ー you're having profit-taking there."
The sell-off adds to October's market losses ー the S&P 500 is now down five days in a row, its longest losing streak since before the 2016 election ー with investors worried about the impact of ongoing trade tensions and borrowing costs at seven-year highs.
While tech stocks were among Wednesday's biggest losers, high-end retailers also took a hit. France's LVMH warned it was seeing slower demand from Chinese consumers, an indication that tariffs from the U.S. were eating into discretionary budgets. Shares of Tiffany ($TIF), Michael Kors ($KORS), and Ralph Lauren ($RL) were all down.
The Nasdaq led losses among the broad market indexes, falling more than 3 percent. For the month, it's already down nearly 8 percent, its biggest monthly decline since January 2016.
Meridith McGraw, White House Reporter at The Wall Street Journal, breaks down Trump’s $200M ballroom plan, D.C. police tensions, and the future of MAGA.
After years of being told that red wine was good for heart health, more Americans appear to be heeding warnings that even moderate alcohol consumption can be unhealthy.
Amazon is now rolling out a service where its Prime members can order their blueberries and milk at the same time as their batteries and other basic items.
Dr. Richard Besser, President & CEO of the Robert Wood Johnson Foundation and former CDC acting director, unpacks the impact of RFK's mRNA funding cuts.
Jessica Inskip, Director of Investor Research at StockBrokers.com and host of MarketMakeHer, unpacks earnings, market outlook, and what history says is next.
